- Sales Intelligence: Healthcare
- Posts
- Weekly Newsletter - 11.27.2024
Weekly Newsletter - 11.27.2024
PLUS: Why personalized engagement strategies are now a must in the world of healthcare sales
Subscribe | Forward | Follow on LinkedInš
Welcome to Sales Intelligence: Healthcare, the weekly newsletter for healthcare sales professionals. Now is the time to fine-tune your strategies, leverage cutting-edge insights, and ensure your campaigns not only engage but convert.

By Laura Keith, CEO of Hive Perform
What if the metrics youāre focused on arenāt the ones that really drive success? Hive Perform CEO Laura Keith believes sales teams are often looking in the wrong place. In her latest article, she explains why leading indicatorsāthose controllable daily actions like outreach, follow-ups, and discovery callsāare what truly shape long-term outcomes.
Laura dives into:
The difference between leading and lagging indicators.
Why leading indicators are more critical now than ever.
How focusing on these daily actions empowers teams and builds ownership.
Donāt just measure resultsāstart influencing them. Read Lauraās full insights and discover how to shape your future success.

INDUSTRY INSIGHTS š
Understanding the pharma market's shifting dynamics, such as the rise of generic competitors and empowered patients, is vital for sales teams today. Personalized engagement strategies tailored to specific demographics can make a brand stand out.
Targeting healthcare professionals is key, as they influence prescription trends. Building trust through medical conferences, webinars, and educational content is essential. Patient-centric marketing focuses on empathy and transparency, using testimonials and educational videos to foster trust. Digital marketing, a game-changer, involves email campaigns, SEO-optimized blogs, and targeted PPC ads. AI revolutionizes campaigns by analyzing data and personalizing outreach.
Navigating regulatory compliance is critical, with adherence to FDA guidelines and legal consultation ensuring lawful marketing. Data analytics refine strategies by analyzing prescription trends and campaign performance. Influencer marketing, involving medical experts or patient advocates, amplifies reach. Social media fosters engagement and humanizes pharma brands. Multichannel approaches optimize ROI by tailoring messages for each platform. By embracing these strategies, pharma marketers not only boost sales but also transform lives, ensuring long-term success.
Lakshdeep Singh's innovative integration of AI and machine learning into healthcare technology has significantly advanced patient care and pharmaceutical operations. As a senior principal at IQVIA, Singh leverages his background in electronics, communication, and business to lead projects that enhance decision-making processes in the life sciences industry. His work focuses on predictive analytics, enabling pharmaceutical companies to optimize sales strategies and improve patient engagement.
Singh's 'Promotional Alerts' program exemplifies his impact, using AI to predict patient needs and facilitate timely medical interventions. This approach has been adopted by over 50 pharmaceutical companies, demonstrating the transformative potential of data-driven solutions in healthcare.

INDUSTRY NEWS š°
Sean Zam has been appointed head of sales and marketing at GC Biopharma USA, bringing extensive experience in the pharmaceutical industry. Known for his success in plasma therapeutics, Zam's values align with GC Biopharma's focus on relationships and community service, enhancing their leadership team and business approach.
Lupin Limited has launched Bumetanide Injection USP in the U.S. for treating edema linked to heart failure, liver, and kidney diseases. Approved by the U.S. FDA, this generic version of Bumex Injection is expected to capture a share of the $20 million market, enhancing treatment accessibility.
Lexicon Pharmaceuticals is undergoing a significant restructuring to save $100 million in operating costs next year. This decision follows a setback with the FDA regarding the approval of its diabetes drug, Zynquista. The FDA highlighted deficiencies in Lexicon's application, leading the company to disband its sales team and lay off 60 employees. This move marks a shift in focus towards its research pipeline, which includes a Phase 2 drug for diabetic peripheral neuropathic pain and a preclinical obesity therapy.

YOUR FEEDBACK MATTERSš³ļø
What type of content would you like to see more of in our newsletter? |


Sales Intelligence is a Contentive publication in the Sales & Marketing division